发明申请
US20120114667A1 TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
审中-公开
针对5BETA1的针对性结合剂及其用途
- 专利标题： TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
- 专利标题（中）： 针对5BETA1的针对性结合剂及其用途
-
申请号： US13141564申请日： 2009-12-21
-
公开(公告)号： US20120114667A1公开(公告)日： 2012-05-10
- 发明人: Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
- 申请人： Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
- 申请人地址： GB Cambridge
- 专利权人： MEDIMMUNE LIMITED
- 当前专利权人： MEDIMMUNE LIMITED
- 当前专利权人地址： GB Cambridge
- 国际申请： PCT/EP09/67706 WO 20091221
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; C07K16/18 ; C07H21/04 ; C12N15/63 ; C12N5/16 ; C12P21/06 ; A61P35/00 ; C07K14/00 ; A61K38/00 ; A61P29/00 ; A61P9/10 ; A61P9/00 ; A61P5/00 ; C12N5/10 ; C07K16/00
摘要：
The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.
信息查询
